Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 20 2025
0mins
Source: Yahoo Finance
FDA Meeting Outcome: Awakn Life Sciences Corp. received positive feedback from the FDA during its Pre-IND meeting regarding the development of AWKN-002, an oral thin film formulation of esketamine for treating moderate to severe alcohol use disorder (AUD), confirming no additional clinical data is needed before starting Phase 2b trials.
Significance of AUD Treatment: With approximately 29 million adults affected by AUD in the U.S., and treatment success rates being low, Awakn aims to address this significant unmet medical need through innovative therapeutics, emphasizing the importance of their ongoing research and development efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
